◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CAPR

Capricor Therapeutics Inc (CAPR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-01

Capricor Therapeutics Inc (CAPR) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 231 employees. Its market capitalization is roughly $479 million. In the fiscal year ended 2025-12-31, CAPR reported $0M in revenue and ($105M) in net income.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Interactive charts & full statements →

CAPR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$0M	$0M	$22M	$25M	$3M	$0M	$0M	$1M	$2M	$1M	$3M	$4M	$4M	$1M	$0M	$1M	—	—	—	$0M	$0M
Gross Profit	—	—	($28M)	($11M)	($19M)	$0M	$0M	($4M)	$2M	$1M	$3M	($10M)	($3M)	$1M	$0M	$1M	—	—	—	$0M	$0M
Gross Margin %	—	—	-124.4%	-44.8%	-755.1%	100.0%	100.0%	-411.6%	100.0%	100.0%	100.0%	-264.3%	-72.0%	100.0%	100.0%	100.0%	—	—	—	100.0%	100.0%
Operating Income (EBIT)	($135M)	($108M)	($43M)	($24M)	($30M)	($21M)	($14M)	($8M)	($15M)	($13M)	($17M)	($13M)	($6M)	($7M)	($2M)	($5M)	($6M)	($8M)	($13M)	($10M)	$0M
Operating Margin %	—	—	-191.1%	-95.6%	-1163.9%	-8549.9%	-4412.6%	-769.5%	-917.0%	-940.8%	-532.2%	-334.0%	-144.4%	-1371.7%	-1248.1%	-361.6%	—	—	—	-9368.8%	-15.9%
Net Income	($129M)	($105M)	($40M)	($22M)	($29M)	($20M)	($14M)	($8M)	($15M)	$2M	($19M)	($13M)	($6M)	($9M)	($2M)	($5M)	($6M)	($8M)	($13M)	($10M)	$0M
Net Margin %	—	—	-181.7%	-88.5%	-1137.4%	-8175.9%	-4401.9%	-760.4%	-908.9%	177.8%	-589.5%	-340.5%	-149.2%	-1767.0%	-968.3%	-360.5%	—	—	—	-10160.8%	-16.1%
EBITDA	$1.2B	($100M)	($39M)	($21M)	($28M)	($20M)	($14M)	($8M)	($15M)	($13M)	($17M)	($13M)	($6M)	($7M)	($2M)	($5M)	($6M)	($8M)	($13M)	($9M)	$0M
Earnings Per Share (EPS)	$-2.45	$-2.26	$-1.15	$-0.83	$-1.18	$-0.87	$-0.88	$-2.06	$-5.17	$0.91	$-10.14	$-8.09	$-5.32	$-8.47	$-22.43	$-65.43	$-93.74	$-154.56	$-272.15	$-304.07	$-2.22
Shares Outstanding (M)	58M	46M	35M	27M	25M	23M	16M	4M	3M	3M	2M	2M	1M	1M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$11M	$2M
Gross Profit	—	—	—	($20M)	($22M)	($19M)	($3M)	($10M)
Gross Margin %	—	—	—	—	—	—	-30.8%	-422.1%
Operating Income (EBIT)	($43M)	($37M)	($29M)	($26M)	($28M)	($25M)	($8M)	($13M)
Operating Margin %	—	—	—	—	—	—	-69.2%	-575.2%
Net Income	($41M)	($34M)	($30M)	($25M)	($26M)	($24M)	($7M)	($13M)
Net Margin %	—	—	—	—	—	—	-63.9%	-555.2%
EBITDA	$255M	($33M)	$976M	($24M)	($25M)	($24M)	($7M)	($12M)
Earnings Per Share (EPS)	$-0.70	$-0.59	$-0.62	$-0.54	$-0.57	$-0.53	$-0.20	$-0.38
Shares Outstanding (M)	58M	57M	49M	46M	46M	46M	35M	33M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($104M)	($70M)	($40M)	($26M)	$5M	($17M)	($10M)	($7M)	($14M)	($14M)	($16M)	($11M)	$1M	($6M)	($2M)	($5M)	($4M)	($6M)	($11M)	($5M)	$0M
Capital Expenditures (CapEx)	$26M	$3M	$2M	$2M	$3M	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($130M)	($73M)	($42M)	($28M)	$2M	($18M)	($11M)	($7M)	($14M)	($14M)	($16M)	($11M)	$1M	($6M)	($2M)	($5M)	($4M)	($6M)	($11M)	($6M)	$0M
FCF Margin %	—	—	-186.5%	-109.8%	61.0%	-7352.3%	-3417.4%	-733.2%	-848.3%	-1043.2%	-501.4%	-290.5%	18.5%	-1242.6%	-1125.4%	-343.3%	—	—	—	-5583.4%	-14.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($31M)	($29M)	($24M)	($20M)	($20M)	($6M)	($15M)	($12M)
Capital Expenditures (CapEx)	$6M	$11M	$5M	$4M	$1M	$1M	$1M	$0M
Free Cash Flow (FCF)	($37M)	($40M)	($29M)	($24M)	($22M)	($8M)	($16M)	($12M)
FCF Margin %	—	—	—	—	—	—	-139.5%	-517.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CAPR Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$369M	$356M	$170M	$59M	$50M	$41M	$35M	$11M	$9M	$16M	$19M	$16M	$14M	$6M	$5M	$1M	$4M	$4M	$6M	$17M	$0M
Cash & Cash Equivalents	$21M	$288M	$11M	$15M	$10M	$35M	$33M	$4M	$4M	$6M	$16M	$14M	$8M	$2M	$0M	$1M	$3M	$3M	$6M	$16M	$0M
Total Liabilities	$123M	$50M	$25M	$36M	$38M	$10M	$6M	$4M	$5M	$5M	$23M	$17M	$20M	$6M	$1M	$1M	$1M	$1M	$1M	$2M	$0M
Total Debt (Short + Long-Term)	$1M	$4M	$1M	$1M	$4M	$4M	$0M	$3M	$3M	$3M	$31M	$10M	$18M	$4M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$246M	$306M	$145M	$23M	$12M	$31M	$28M	$7M	$5M	$11M	($4M)	($1M)	($6M)	($1M)	$5M	$1M	$3M	$3M	$5M	$15M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CAPR viewer.

Other Companies in BIOTECHNOLOGY

FTH · Faeth Therapeutics, Inc. — $508 million
RGNX · Regenxbio Inc — $504 million
OVID · Ovid Therapeutics Inc — $496 million
CBIO · Crescent Biopharma, Inc. — $485 million
CTMX · CytomX Therapeutics Inc — $475 million
MDXG · MiMedx Group Inc — $474 million
GYRE · Gyre Therapeutics Inc. — $471 million
OCS · Oculis Holding AG Ordinary shares — $470 million

← CAPQ All “C” companies CAPS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.